Compare Summit Therapeutics Inc (SMMT) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Western Digital Corp — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Western Digital Corp trades at $480.81 (market cap $172.09B). The key difference: Western Digital Corp is far larger — about 12.5× Summit Therapeutics Inc's market cap, and Western Digital Corp pays a 0.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WDC | |
|---|---|---|
Market Cap | $13.79B | $172.09B |
Sector | Health | Technology |
52-Week High | $26.38 | $746.23 |
52-Week Low | $12.43 | $95.03 |
Enterprise Value | $13.11B | $171.56B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Western Digital (WDC) trades at $477.30, up 2.1% today, reflecting strong momentum amid AI-driven storage demand. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $676.70 suggesting 42% upside. Fundamentals are robust, with a net income margin of 71.97% in 2025 and positive cash flow trends, though revenue declined to $9.52B from prior years.
Outlook remains positive due to AI data growth catalysts and shareholder returns, but risks include competitive pressures and volatility from high expectations. The stock's valuation multiples like P/E of 17.73 appear reasonable given growth prospects, supporting a bullish bias with caution on execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
